Top Medical News
Which factors predict mortality in advanced HCC?
8 hours ago
A study has found the high bilirubin, pretreatment hypoalbuminemia, and biochemical tests indicative of hepatic or renal dysfunctions are independently associated with short-term mortality in patients with advanced hepatocellular cancer (HCC) receiving atezolizumab and bevacizumab (Atezo/Bev).
Hepatitis E vaccine offers durable protection
4 days ago
Vaccination against hepatitis E appears to provide up to 10 years of protection, with vaccine-induced antibodies persisting for at least 8.5 years, as shown in a study from China.
Hypercholesterolemia linked to poor prognosis in primary biliary cholangitis
16 Feb 2024
In patients with primary biliary cholangitis (PBC), elevated total cholesterol levels are associated with dysregulation of lipid metabolism and may lead to poor clinical outcomes, as shown in a study.
High levels of salt added to food up CKD risk
Elaine Soliven, 16 Feb 2024

Frequently adding salt to food significantly increases the risk of chronic kidney disease (CKD) in the general population, according to a recent study.

Alcohol abstinence boosts overall survival in alcohol-associated cirrhosis
15 Feb 2024
Abstinence from alcohol may dramatically increase survival rates for individuals with alcohol-related cirrhosis, as reported in a study.
Dietary niacin may protect against death in NAFLD
Jairia Dela Cruz, 13 Feb 2024
Dietary niacin intake may benefit individuals with nonalcoholic fatty liver disease (NAFLD), with a study suggesting that a higher intake lowers the risk of mortality.
Immunotherapy, TACE-based regimen may reshape HCC treatment landscape
Audrey Abella, 13 Feb 2024
In the EMERALD-1 trial, durvalumab plus bevacizumab (D+B) combined with transarterial chemoembolization (TACE) improved progression-free survival (PFS) in individuals with unresectable hepatocellular carcinoma (HCC) eligible for embolization.
Special Reports
Keeping up to date in primary care: Insights from IMPACT
16 Jul 2020
Updated health information is crucial for healthcare professionals to improve their knowledge in providing healthcare services. During a series of talks at the IMPACT GP Symposium 2020 held in Singapore on 11 January 2020, a panel of specialists shared insights on current treatment approaches for atopic dermatitis and wound healing, as well as updates from the 2019 dyslipidaemia guidelines and on the management of fatty liver disease.
Response redefined with the power of lenvatinib in first-line unresectable HCC therapy
Dr. David Tai, Dr. Yong Wei Peng, 26 Nov 2019
Systemic therapy plays a central role in the management of unresectable hepatocellular carcinoma (HCC). In this rapidly developing therapy area, recent clinical trials are redefining systemic treatments, including multiple kinase inhibitors (MKI). During the recent Gastro Lunch and Learn sessions sponsored by Eisai, Dr David Tai and Dr Yong Wei Peng discussed the evidence behind MKIs such as lenvatinib (Lenvima®) in the treatment of unresectable HCC through a case-based approach.
Reducing risks and improving long-term outcomes in patients with CHB
Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
Relationship between tumour response to systemic therapy and overall survival in unresectable hepatocellular carcinoma
Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).  

Risk of HCC lower with tenofovir than entecavir
in chronic hepatitis B patients
20 Mar 2019
Current guidelines for the treatment of chronic hepatitis B (CHB) recommend entecavir (ETV), tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF) as first-line oral agents. [Hepatology 2018;67:1560-1599; Hepatol Int 2016;10:1-98; J Hepatol 2017;67:370-398] TAF, like TDF, is a phosphonate prodrug of tenofovir. Whether tenofovir is superior to entecavir in specific clinical settings, or both antivirals have comparable clinical outcomes in real-world cohorts, remains to be extensively studied as these would have considerable implications for practice and the prevention of hepatocellular carcinoma (HCC) in the CHB population.
Conference Reports
Aspirin reduces liver fat, improves markers of inflammation, fibrosis
Elvira Manzano, 04 Jan 2024
Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) – previously called nonalcoholic fatty liver disease (NAFLD) – but without  cirrhosis, who were treated with daily low-dose aspirin, had significant reductions in liver fat for 6 months in a new trial.
Resmetirom reduces bad cholesterol, restores thyroid hormones in NASH
Elaine Soliven, 12 Dec 2023

Treatment with resmetirom significantly reduced low-density lipoprotein cholesterol (LDL-C) and other atherogenic lipids, as well as restored thyroid hormone (TH) levels in patients with nonalcoholic steatohepatitis (NASH), according to two subgroup analyses of the MAESTRO-NASH trial presented at The Liver Meeting 2023.

Seladelpar improves markers of cholestasis, reduces pruritus in patients with PBC
Elaine Soliven, 01 Dec 2023

Treatment with seladelpar significantly improves serum markers of cholestasis, including alkaline phosphatase (ALP) and total bilirubin (TB), and reduces pruritus in patients with primary biliary cholangitis (PBC) who are at risk for disease progression, according to the RESPONSE trial presented at The Liver Meeting 2023.

Novel tri-agonist confers significant gains for MASLD patients
Audrey Abella, 24 Nov 2023
In a substudy of a phase II obesity trial, individuals with MASLD* and obesity benefited significantly from retatrutide, a once-weekly, injectable, novel synthetic molecule that has shown potent agonist action at GIP**, GLP-1***, and glucagon receptors.
HBV vaccine improves survival of patients with chronic liver disease
Stephen Padilla, 22 Nov 2023
Vaccination against hepatitis B virus (HBV) results in meaningful improvements in survival among patients with different kinds of chronic liver diseases, suggests a study presented at AASLD 2023.
Can elexacaftor/tezacaftor/ivacaftor cause liver damage in adults with cystic fibrosis?
Stephen Padilla, 21 Nov 2023
Treatment with elexacaftor/tezacaftor/ivacaftor (ETI) rarely results in severe drug-induced liver injury among adults with cystic fibrosis, as shown in a study presented at AASLD 2023. Moreover, serum markers of fibrosis have increased but remain within normal range.
Bulevirtide-PegIFNα combo yields benefits for CHD patients
Audrey Abella, 21 Nov 2023
A combination regimen comprising bulevirtide 10 mg (BLV10) and pegylated interferon alpha-2a (PegIFNα) improved multiple liver parameters in patients with chronic hepatitis delta (CHD), findings from the phase IIb MYR204 study have shown.